XFOR FY2027 EPS Lowered by Brookline Capital Management

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Research analysts at Brookline Capital Management reduced their FY2027 earnings estimates for X4 Pharmaceuticals in a research note issued to investors on Thursday, February 6th. Brookline Capital Management analyst L. Cann now forecasts that the company will earn $0.36 per share for the year, down from their previous forecast of $0.42. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share.

XFOR has been the subject of a number of other research reports. HC Wainwright reiterated a “buy” rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a report on Friday, February 7th. Stifel Nicolaus decreased their price objective on X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, November 14th.

X4 Pharmaceuticals Trading Down 8.0 %

Shares of NASDAQ:XFOR opened at $0.47 on Monday. The firm has a market cap of $79.94 million, a price-to-earnings ratio of -5.21 and a beta of 0.12. X4 Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $1.60. The company’s fifty day simple moving average is $0.60 and its 200 day simple moving average is $0.60. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26.

Insider Buying and Selling at X4 Pharmaceuticals

In related news, CEO Paula Ragan sold 76,473 shares of the firm’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the completion of the transaction, the chief executive officer now directly owns 1,087,386 shares of the company’s stock, valued at approximately $489,323.70. This trade represents a 6.57 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Adam S. Mostafa sold 74,773 shares of the company’s stock in a transaction on Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The disclosure for this sale can be found here. In the last three months, insiders have sold 202,663 shares of company stock worth $91,198. Insiders own 1.62% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. State Street Corp grew its holdings in X4 Pharmaceuticals by 6.8% during the third quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after purchasing an additional 189,105 shares during the period. Verition Fund Management LLC bought a new stake in X4 Pharmaceuticals in the third quarter valued at approximately $30,000. SG Americas Securities LLC acquired a new stake in shares of X4 Pharmaceuticals in the third quarter valued at approximately $37,000. XTX Topco Ltd boosted its stake in shares of X4 Pharmaceuticals by 41.7% during the 3rd quarter. XTX Topco Ltd now owns 157,642 shares of the company’s stock worth $106,000 after acquiring an additional 46,397 shares during the period. Finally, Jane Street Group LLC increased its holdings in shares of X4 Pharmaceuticals by 103.4% during the 3rd quarter. Jane Street Group LLC now owns 248,447 shares of the company’s stock worth $166,000 after acquiring an additional 126,296 shares during the last quarter. 72.03% of the stock is currently owned by institutional investors and hedge funds.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.